New and Evolving Therapeutic Targets in Lung Cancer: Expert Guidance in Incorporating Biomarker Testing to Deliver Precision Therapy

Download All
Gain expert insights on how to test for new and emerging molecular targets and incorporate targeted agents into the care of your patients with lung cancer with downloadable slides and on-demand Webcasts from live meetings, biomarker summary handouts, and a decision support tool providing the latest individualized guidance on precision therapy for NSCLC.
Todd M. Bauer, MD
Lyudmila Bazhenova, MD
Edward S. Kim, MD, FACP, FASCO
person default
Vamsidhar Velcheti, MD


Which emerging biomarkers have the most potential to affect personalized care of our patients with NSCLC? Read my thoughts on testing for and targeting RET, MET exon 14, and more.

Todd M. Bauer, MD Released: February 28, 2020

As targeted therapy prolongs survival in our patients with oncogene-driven NSCLC, CNS metastases and leptomeningeal carcinomatosis are more likely to develop as part of the disease course. Read my thoughts on what factors I consider when treating these challenging disease manifestations.

Lyudmila Bazhenova, MD Released: April 28, 2020

Vamsidhar Velcheti, MD, provides his thoughts on the clinical implications of the recent approval of selpercatinib for RET fusion–positive NSCLC in this commentary.

person default Vamsidhar Velcheti, MD Released: June 25, 2020

Are you aware of emerging options for the treatment of advanced HER2-mutated NSCLC? Read my thoughts on a new therapy showing promise to improve outcomes in these patients.

Edward S. Kim, MD, FACP, FASCO Released: October 22, 2020
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from

For further information concerning Lilly grant funding, visit

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings